Omada Health (OMDA) Q3 2026 Earnings Call Transcript

Omada Health reported Q3 2026 revenue of $91.3 million, up 34% year over year, and net income of $6.6 million versus a $3.2 million loss a year earlier; adjusted EBITDA reached a quarterly record of $12.4 million. Gross margin expanded to 76% GAAP and 78% non-GAAP, while management raised 2026 revenue guidance to $344 million–$346 million and adjusted EBITDA guidance to $32 million–$34 million. The company cited 1.13 million members, lower care costs supported partly by AI, and an HCSC expansion covering an estimated additional 1.5 million lives beginning in phases in 2027; it expects Q4 revenue to decline sequentially with seasonal enrollment. President Wei-Li Shao is set to become CEO on Jan. 1, 2027, as co-founder Sean Duffy transitions to executive chair.

Analysis

The key debate is whether margin expansion is a repeatable cohort effect or a seasonal high-water mark. Longer-tenured members appear to add gross profit with less incremental care cost, but lower billing frequency means retention alone cannot replace enrollment: weaker new-member conversion could lift margin while slowing revenue per member and growth. Watch enrollment yield and revenue per member together, not either metric in isolation.

Distribution through PBMs and HCSC can lower customer-acquisition friction, but it also shifts leverage toward large intermediaries and exposes Omada to buyer demands for ROI guarantees. As healthcare budgets tighten, outcome-based contracts may support wins while putting more downside risk on Omada if clinical results or utilization diverge from assumptions. HCSC’s covered lives are a phased opportunity, not near-term enrolled members. GLP-1 coverage retrenchment is two-sided: FlexCare may capture users outside employer drug benefits, but willingness to pay for support without drug coverage remains unproven. Independently verify the cited outcomes and FlexCare adoption before underwriting that upside.

Over the next 1–3 months, holiday seasonality, later employer decisions and planned hiring can temper sequential results and obscure demand. The 2027 HCSC rollout, sales close rates and enrollment conversion are the more useful catalysts. Over 6–18 months, AI-supported care efficiency and multi-condition adoption could sustain operating leverage; the incoming CEO transition adds execution risk, though no immediate operational disruption is established. No valuation or post-call price data are provided, so avoid chasing a headline-driven move. A thesis failure would be declining enrollment yield, slowing revenue/member, weaker gross-margin progression, or guidance pressure tied to delayed launches or guarantee costs.

Key Decisions for Investors

• Treat OMDA as a conditional long/watchlist rather than a momentum chase: consider staged entry after any post-results volatility, and size against the risk that Q4 seasonality masks weakening underlying conversion. No price level or valuation case is available here.
• Track quarterly enrollment yield, revenue per member, member tenure and gross margin together. If retention rises but enrollment and revenue/member weaken, reduce the growth thesis rather than extrapolating margin gains.
• Use the 2027 HCSC phased launch and employer selling-season outcomes as catalysts; verify lives actually activated, enrollment conversion and revenue contribution before crediting the full covered-life opportunity.
• Monitor the share of contracts with clinical or ROI guarantees and any disclosed performance shortfalls. Rising at-risk exposure without corresponding margin or retention gains would argue against adding to OMDA.
• Do not underwrite GLP-1 FlexCare as an offset to reduced drug coverage until employer adoption and member economics are disclosed; the reported clinical comparison is not, by itself, proof of commercial demand or savings.